13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001617201
Total reported value
$580.4M
$580.4M
44 檔
24.1%
In Q1 2024, Prosight Management, LP's U.S. equity holdings reached a combined market value of $580.4M, distributed across 44 disclosed stock positions.
During Q1 2024, Prosight Management, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | STTK | Shattuck Labs Inc | Stock-Other | 9.26% | +1.84% | +33.86% | |
| 2 | ✓ | Adc Therapeutics SA | Stock-Other | 8.81% | -3.66% | +8.94% | |
| 3 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 8.34% | +2.93% | +12.60% | |
| 4 | MGTX | MeiraGTx Holdings plc | Stock-Other | 6.78% | -3.52% | -0.82% | |
| 5 | KURA | Kura Oncology Inc | Stock-Other | 5.70% | -0.66% | +1.05% | |
| 6 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 5.45% | -0.82% | EXIT | |
| 7 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 5.07% | — | — | |
| 8 | CYTK | Cytokinetics Inc | Stock-Healthcare | 4.78% | — | — | |
| 9 | MDT | Medtronic plc | Stock-Healthcare | 4.36% | — | -18.18% | |
| 10 | KIDS | Orthopediatrics CORP | Stock-Other | 3.39% | -0.27% | +340.27% | |
| 11 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 3.25% | — | +58.54% | |
| 12 | GH | Guardant Health Inc | Stock-Healthcare | 2.70% | — | — | |
| 13 | KELYA | Kelly Services Inc -a | Stock-Other | 2.43% | — | — | |
| 14 | ABCL | Abcellera Biologics Inc | Stock-Other | 2.26% | — | +5.29% | |
| 15 | ERAS | Erasca Inc | Stock-Other | 2.10% | — | +510.51% | |
| 16 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.98% | — | -37.28% | |
| 17 | IMVT | Immunovant Inc | Stock-Other | 1.75% | -0.72% | EXIT | |
| 18 | PFE | Pfizer Inc | Stock-Healthcare | 1.66% | +0.56% | NEW | |
| 19 | ALKS | Alkermes plc | Stock-Healthcare | 1.62% | +0.58% | +1333.33% | |
| 20 | UHS | Universal Health Services-b | Stock-Healthcare | 1.52% | — | +6.80% | |
| 21 | MRVI | Maravai Lifesciences Hldgs-a | Stock-Other | 1.45% | — | — | |
| 22 | ZYME | Zymeworks Inc | Stock-Other | 1.20% | +0.83% | — | |
| 23 | PRTA | Prothena Corporation plc | Stock-Other | 1.17% | — | -25.73% | |
| 24 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.17% | — | -15.04% | |
| 25 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.10% | -0.02% | — | |
| 26 | RLAY | Relay Therapeutics Inc | Stock-Other | 1.04% | — | — | |
| 27 | COGT | Cogent Biosciences Inc | Stock-Other | 1.04% | — | — | |
| 28 | OPCH | Option Care Health Inc | Stock-Healthcare | 0.93% | +0.98% | NEW | |
| 29 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.89% | -0.24% | EXIT | |
| 30 | DXCM | Dexcom Inc | Stock-Healthcare | 0.89% | — | — | |
| 31 | BBSI | Barrett Business Svcs Inc | Stock-Other | 0.85% | — | +84.62% | |
| 32 | OVID | Ovid Therapeutics Inc | Stock-Other | 0.83% | — | — | |
| 33 | PCRX | Pacira Biosciences Inc | Stock-Other | 0.77% | — | -63.49% | |
| 34 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 0.69% | — | — | |
| 35 | ✓ | Mural Oncology Pub LTD Co | Stock-Other | 0.54% | — | -4.42% | |
| 36 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.40% | — | — | |
| 37 | TXG | 10x Genomics Inc-class A | Stock-Other | 0.31% | — | — | |
| 38 | BMEA | Biomea Fusion Inc | Stock-Other | 0.31% | — | +74.46% | |
| 39 | NUVB | Nuvation Bio Inc | Stock-Other | 0.25% | — | -87.80% | |
| 40 | PRVA | Privia Health Group Inc | Stock-Other | 0.25% | — | -65.95% | |
| 41 | ✓ | Stock-Other | 0.24% | — | -71.37% | ||
| 42 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 0.20% | — | — | |
| 43 | ✓ | Stock-Other | 0.20% | — | — | ||
| 44 | ABSI | Absci CORP | Stock-Other | 0.04% | — | — |
According to official SEC Form 13F filings, Prosight Management, LP reported a total U.S. public equity portfolio value of $580.4M across 44 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including STTK, ADC THERAPEUTICS SA, LKFT) accounted for 24.1% of total reported equity market value during Q1 2024.
During Q1 2024, Prosight Management, LP's top holdings by market value included STTK (9.3%)、ADC THERAPEUTICS SA (8.8%)、LKFT (8.3%). The largest single position, STTK, represented 9.3% of total portfolio value.
In Q1 2024, Prosight Management, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.